(NASDAQ: RLAY) Relay Therapeutics's forecast annual revenue growth rate of 44.37% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.01%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Relay Therapeutics's revenue in 2025 is $7,679,000.On average, 4 Wall Street analysts forecast RLAY's revenue for 2025 to be $3,272,370,066, with the lowest RLAY revenue forecast at $1,320,126,238, and the highest RLAY revenue forecast at $6,463,475,218. On average, 3 Wall Street analysts forecast RLAY's revenue for 2026 to be $7,566,895,019, with the lowest RLAY revenue forecast at $2,571,674,490, and the highest RLAY revenue forecast at $13,237,265,825.
In 2027, RLAY is forecast to generate $1,466,711,684 in revenue, with the lowest revenue forecast at $308,600,939 and the highest revenue forecast at $2,624,822,429.